Skip to main content

Prologis Inc(PLD-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low127.62
Day High130.92
Open:127.97
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Press & news

Latest News

Prologis Announces Tax Treatment of Duke Realty Corporation's 2022 Dividends
PR Newswire - Thu Jan 26, 3:54PM CST
PR Newswire
Thu Jan 26, 3:54PM CST
/PRNewswire/ -- Prologis, Inc. (NYSE: PLD), the global leader in logistics real estate, today announced the tax treatment of Duke Realty Corporation (NYSE:...
Prologis Announces Tax Treatment of 2022 Dividends
PR Newswire - Thu Jan 26, 3:54PM CST
PR Newswire
Thu Jan 26, 3:54PM CST
/PRNewswire/ -- Prologis, Inc. (NYSE: PLD), the global leader in logistics real estate, today announced the tax treatment of its 2022 distributions. Exhibits A...
2 Stocks to Buy In 2023 to Help You Retire Early
Motley Fool - Thu Jan 26, 5:46AM CST
Motley Fool
Thu Jan 26, 5:46AM CST
These companies have a track record of dividend growth with plenty of coverage to keep growing.

Latest Articles

Weekly Summary Corporate dividends, name changes, new listings
Weekly Summary Corporate dividends, name changes, new listings
Prologis and Western Digital climb; Pfizer skids